<div><div></div><div><span><p><strong><span>Jade Bios announced pricing of a 10,000,000-share public offering at $15.00 per share, expected to raise about $140.3 million net.</span></strong></p><p><strong><span>Key Highlights:</span></strong></p><ul><li><span>Underwriters priced 10,000,000 shares at $15.00 each; gross proceeds $150.0M before fees and expenses.</span></li><li><span>Underwriters to buy shares from the company at $14.10 per share, with customary underwriting terms and indemnities.</span></li><li><span>Company granted a 30-day option for up to 1,500,000 additional shares (15%); net proceeds could reach ~$161.5M if exercised.</span></li><li><span>Net proceeds expected to be approximately $140.3M after discounts, commissions and expenses; closing expected June 5, 2026.</span></li><li><span>Proceeds intended to fund clinical trials, preclinical studies, manufacturing, R&amp;D, capex, working capital and general corporate purposes.</span></li></ul><p><span>Original SEC Filing: </span>Jade Biosciences, Inc. [ JBIO ] - 8-K - Jun. 04, 2026</p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

JBIO

<p>Jade Bios priced a follow-on public offering of 10 million shares at $15.00 per share, raising approximately $140.3 million in net proceeds. The company has a 30-day option to sell an additional 1.5 million shares. Net proceeds will fund clinical trials, R&D, manufacturing, and general corporate purposes. The transaction is expected to close on June 5, 2026.</p>

Jade Bios prices $150M follow-on offering, 10M shares at $15; nets ~$140.3M